BDCA2 NFAT Luciferase Reporter Jurkat Cell Line

BDCA2 NFAT Luciferase Reporter Jurkat Cell Line is a Jurkat cell line that expresses human BDCA2 (Blood Dendritic Cell Antigen 2), adapter FcepsilonRIgamma (Fc epsilon receptor I), and the firefly luciferase reporter under the control of NFAT (Nuclear Factor of Activated T-cells) response elements located upstream of the minimal TATA promoter. BDCA2 expression was verified by flow cytometry, and this cell line was functionally validated with the anti-BDCA2 antibody Litifilimab in co-culture assays. Figure 1: Representation of the mechanism of action of BDCA2 NFAT Luciferase Reporter Jurkat Cell Line in a co-culture assay with FcGR2B CHO Cell Line in the presence of Litifilimab. Interested in screening and profiling molecules targeting BDCA2 without the need to purchase and license the cell line? Check out our Immunotherapy Cell-Based Screening Services. Blood Dendritic Cell Antigen 2 (BDCA2), also known as CD303 or CLEC4C, is a type II C-type lectin specifically expressed on human plasmacytoid dendritic cells (pDCs). It is a glycan-binding receptor that inhibits the production of type I interferon. BDCA2 does not contain any signaling motifs, and it triggers signaling through the high-affinity IgE receptor FcepsilonRIgamma, inducing a B cell receptor (BCR)-like cascade. Binding to BDCA2 results in inhibition of TLR7 (Toll-like receptor 7) and TLR9-induced production of IFN-I (interferon) and other pro-inflammatory cytokines. IFN-I is linked to SLE (systemic lupus erythematosus), therefore BDCA2 has become an attractive therapeutic target in autoimmunity. Litifilimab, a humanized IgG1 monoclonal antibody targeting BDCA2, was given Breakthrough Therapy Designation by the FDA for the treatment of SLE. Litifilimab binds primarily to BDCA2 but also to FcGR2b, which enhances the inhibitory signal by stabilizing internalization and signal. Further studies into this protein will bring a new understanding of its roles, and new therapies for patients with SLE.